title: Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study.
abstract: To compare the efficacy of antipsychotics (APs) for delirium treatment in patients with cancer, 27 patients treated with 1 of the 4 APs, haloperidol (HPD), risperidone (RIS), olanzapine (OLZ), and quetiapine (QTP), were divided into 2 groups: long half-life (T1/2; HPD, RIS, and OLZ) versus short T1/2 (QTP) or the multiacting receptor-targeted APs (MARTAs; OLZ and QTP) versus the non-MARTA (HPD and RIS). The symptom severity was evaluated by the memorial delirium rating scale (MDAS) on days 0, 3, and 7 following intervention. Significant improvements in total MDAS scores were found in all groups on day 3. However, on day 7, only the short T1/2 group and MARTA group showed significant improvement. Consideration of an AP's pharmacological properties may be helpful for improving the outcomes of pharmacological delirium intervention in patients with cancer.
authors.affiliation: Department of Psychiatry, Osaka University Health Care Center, Toyonaka, Japan Oncology Center, Osaka University Hospital, Suita, Japan tanimuki@psy.med.osaka-u.ac.jp.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Tanimukai
authors.affiliation: Department of Psychiatry, Kansai Rosai Hospital, Amagasaki, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tsujimoto
authors.affiliation: Department of Psychosomatic Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Hospital, Sakai, Japan.
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Matsuda
authors.affiliation: Department of Psychosomatic Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Hospital, Sakai, Japan.
authors.forename: Akihiro
authors.initials: A
authors.lastname: Tokoro
authors.affiliation: Department of Palliative Medicine, Takatsuki Red Cross Hospital, Takatsuki, Japan.
authors.forename: Seitetsu
authors.initials: S
authors.lastname: Kanemura
authors.affiliation: Department of Neuropsychiatry, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
authors.forename: Motoo
authors.initials: M
authors.lastname: Watanabe
authors.affiliation: Department of Psychiatry, Minoh City Hospital, Minoh, Japan.
authors.forename: Ichiro
authors.initials: I
authors.lastname: Tsujio
authors.affiliation: Department of Palliative Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
authors.forename: Isseki
authors.initials: I
authors.lastname: Maeda
authors.affiliation: Department of Palliative Care, Ashiya Municipal Hospital, Ashiya, Japan.
authors.forename: Kiyozumi
authors.initials: K
authors.lastname: Takei
authors.affiliation: Department of Palliative Care, Ashiya Municipal Hospital, Ashiya, Japan.
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Nakajima
authors.affiliation: Department of Psychiatry and Psycho-oncology, Fukuyama City Hospital, Fukuyama, Japan.
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Taira
authors.affiliation: Department of Psychiatry, Toyonaka Municipal Hospital, Toyonaka, Japan.
authors.forename: Madoka
authors.initials: M
authors.lastname: Tokuyama
authors.affiliation: Department of Neuropsychiatry, Osaka City General Hospital, Osaka, Japan.
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Kai
authors.affiliation: Department of Pharmacy, Ashiya Municipal Hospital, Ashiya, Japan.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Okamoto
authors.affiliation: Department of Palliative Care, Osaka Prefectural Medical Center for Respiratory and Allergic Disease, Habikino, Japan.
authors.forename: Sho
authors.initials: S
authors.lastname: Goya
authors.affiliation: Department of Clinical Psychology, Kansai University of Welfare Sciences, Kashiwara, Japan.
authors.forename: Yujiro
authors.initials: Y
authors.lastname: Kashiwagi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000493:pharmacokinetics / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D003693:Delirium / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006207:Half-Life; D006220:Haloperidol / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D000077152:Olanzapine; D000069348:Quetiapine Fumarate / Q000493:pharmacokinetics / Q000627:therapeutic use; D018967:Risperidone / Q000493:pharmacokinetics / Q000627:therapeutic use; D012720:Severity of Illness Index
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D006220:Haloperidol; D018967:Risperidone; D000077152:Olanzapine
keywords: MARTA; MDAS; T half; antipsychotics; delirium; patients with cancer